Introduction {#section5-1753466620937175}
============

Coronavirus disease-2019 (COVID-19) is an emerging infectious disease that has been declared a global public health emergency by the World Health Organization (WHO). Since its inception in Wuhan, China, over 3,500,000 cases and 243,403 deaths have been recorded worldwide.^[@bibr1-1753466620937175]^ Although the majority of patients with COVID-19 have a mild influenza-like illness or may be asymptomatic, a small proportion of patients develop severe pneumonia, acute respiratory distress syndrome (ARDS), multi-organ failure, and can even die.^[@bibr2-1753466620937175]^ The reason why some individuals become critically ill, while others do not, remains an unsolved puzzle. Comorbidities and laboratory markers have been proposed for risk stratification.^[@bibr3-1753466620937175][@bibr4-1753466620937175][@bibr5-1753466620937175]--[@bibr6-1753466620937175]^ There is mounting evidence that in critically ill patients, there are characteristics of hyperinflammation, which consist of elevated serum C-reactive protein (CRP), procalcitonin (PCT), D-dimer, and hyperferritinemia. These findings suggest a possibly crucial role of a cytokine storm in COVID-19 pathophysiology.^[@bibr7-1753466620937175]^

Laboratory biomarkers to forecast the severity of COVID-19 are essential in a pandemic, because resource allocation must be carefully planned, especially in the context of respiratory support readiness. In the present study, we conducted a systematic review and meta-analysis to investigate the association between several biomarkers, including serum CRP, PCT, D-dimer, and serum ferritin, and the severity of COVID-19.

Materials and methods {#section6-1753466620937175}
=====================

Search strategy and study selection {#section7-1753466620937175}
-----------------------------------

A systematic literature search was carried out using the search engines PubMed and EuropePMC with the search terms: (a) 'COVID-19' OR 'SARS-CoV-2' AND 'Characteristics'; (b) ('COVID-19' OR 'SARS-CoV-2' AND 'Characteristics') AND ('Mortality' OR 'SEVERE'), MEDLINE, English, and Human. Additional records were also searched from preprint servers. We excluded duplicates after compiling the results of the initial search. Two independent authors (MAL and IH) sorted the potential articles by screening titles/abstracts. After exclusion of unrelated records, we screened the full text of potential articles for relevance based on the inclusion and exclusion criteria. The search was finalized on 8 April 2020. The study was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guideline.

Inclusion and exclusion criteria {#section8-1753466620937175}
--------------------------------

We included research articles in which samples were adult patients with COVID-19 with data for serum CRP, PCT, D-dimer, and serum ferritin, and reported the data based on the presence or absence of clinically validated definitions of mortality, severe COVID-19, ARDS, and intensive care unit (ICU) care. We excluded review articles, commentaries, letters, original researches with \<20 samples, case reports, non-English language articles, and pediatric populations (\<17 years old).

Data extraction {#section9-1753466620937175}
---------------

Two independent authors (IH and RP) performed data extraction from the included studies using standardized forms that contained author, year, study design, age, gender, cardiovascular diseases, hypertension, diabetes mellitus, chronic obstructive pulmonary disease (COPD), the need for ICU care, serum CRP, PCT, D-dimer, serum ferritin, and severe COVID-19.

The outcome of interest in this meta-analysis was a composite poor outcome, which consisted of mortality, severe COVID-19, ARDS, and need for ICU care. The definition of ARDS in this study was in accordance with the WHO interim guidance of severe acute respiratory infection.^[@bibr8-1753466620937175]^ In this study, severe COVID-19 follows the definition of the WHO--China Joint Commission on COVID-19.^[@bibr9-1753466620937175]^

Statistical analysis {#section10-1753466620937175}
--------------------

For the quantitative analysis, we used the software Review Manager 5.3 (Cochrane Collaboration) and Stata version 16. To calculate the effect estimates for dichotomous variables, we used the Mantel--Haenszel formula to generate the risk ratio (RR) and its 95% confidence interval. For the continuous variables, we used the generic inverse variance method to calculate the effect estimate in the form of standardized mean difference (SMD). To account for inter-study variability, a random-effects model was used, regardless of heterogeneity.

In this meta-analysis, all *p* values reported were two-tailed with the statistical significance set at ⩽ 0.05. A restricted-maximum likelihood random-effects meta-regression analysis was performed for several potentially confounding covariates, including age, gender, hypertension cardiovascular disease, and respiratory comorbidities. The pooled effect estimate for each component of the composite poor outcome was then assessed in the subgroup analysis. Funnel-plot analysis was performed to evaluate qualitatively the risk of publication bias. Regression-based Egger's test was performed to evaluate quantitatively the presence of small-study effects.

Results {#section11-1753466620937175}
=======

Study selection and characteristics {#section12-1753466620937175}
-----------------------------------

Initial record searches yielded 313 records. After removal of duplicates, 300 records remained. After assessing titles/abstracts according to the data of interest, we excluded 253 records and sorted 50 potential records. The potential records were then assessed for their eligibility to be included in this systematic review. A total of 20 articles was excluded because there was no outcome of interest, i.e. mortality, severe COVID-19, ARDS, or need for ICU care. Five other studies were also excluded because there were no dichotomous data for CRP, PCT, and D-dimer, or continuous data for serum ferritin. Thereby, 25 studies were included in the qualitative and quantitative synthesis ([Figure 1](#fig1-1753466620937175){ref-type="fig"}), which comprised 5350 patients.^[@bibr10-1753466620937175][@bibr11-1753466620937175][@bibr12-1753466620937175][@bibr13-1753466620937175][@bibr14-1753466620937175][@bibr15-1753466620937175][@bibr16-1753466620937175][@bibr17-1753466620937175][@bibr18-1753466620937175][@bibr19-1753466620937175][@bibr20-1753466620937175][@bibr21-1753466620937175][@bibr22-1753466620937175][@bibr23-1753466620937175][@bibr24-1753466620937175][@bibr25-1753466620937175][@bibr26-1753466620937175][@bibr27-1753466620937175][@bibr28-1753466620937175][@bibr29-1753466620937175][@bibr30-1753466620937175][@bibr31-1753466620937175][@bibr32-1753466620937175][@bibr33-1753466620937175]--[@bibr34-1753466620937175]^ ([Table 1](#table1-1753466620937175){ref-type="table"}).

![Study flow diagram.\
ARDS, acute respiratory distress syndrome; COVID-19, coronavirus disease-2019; CRP, C-reactive protein; ICU, intensive care unit; PCT, procalcitonin.](10.1177_1753466620937175-fig1){#fig1-1753466620937175}

###### 

Characteristics of the included studies.

![](10.1177_1753466620937175-table1)

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Authors                                       Study design                  Samples          Age (mean/median, years)                                                                                    Male (%)             CRP      CRP cutoff   PCT cutoff     D-dimer cutoff   Ferritin\               DM\                      HTN\                 CAD/CVD (%)               COPD\                             Outcome of interest
                                                                                                                                                                                                                                                                                      mean/median (ng/ml)     (%)                      (%)                                            (%)                               
  --------------------------------------------- ----------------------------- ---------------- ----------------------------------------------------------------------------------------------------------- -------------------- -------- ------------ -------------- ---------------- ----------------------- ------------------------ -------------------- ------------------------- --------------------------------- ---------------------
  Chen *et al.*^[@bibr27-1753466620937175]^     Retrospective Observational   274 (113/161)    68.0 *versus* 51.0                                                                                          73 *versus* 55       hs-CRP   \>100 mg/L   ⩾0.5 ng/ml     \>21 μg/ml       1418.3 *versus* 481.2   21.0 *versus* 14.0       48.0 *versus* 24.0   14.0 *versus* 4.0 (CVD)   10.0 *versus* 4.0 (CLD)           Mortality

  Li *et al.* ^[@bibr26-1753466620937175]^      Retrospective Observational   102 (15/87)      69 *versus* 55                                                                                              73 *versus* 55       hs-CRP   3 mg/L       ⩾0.05 ng/ml    \>1 μg/ml        N/A                     13.0 *versus* 15.0       47.0 *versus* 28.0   13.0 *versus* 2.0         7.0 *versus* 1.0                  Mortality

  Luo *et al.*^[@bibr25-1753466620937175]^      Retrospective Observational   403 (100/303)    71 *versus* 49                                                                                              57 *versus* 44.9     CRP      ⩾100 mg/L    \>0.5 ng/ml    \>5 mg/L         N/A                     25.0 *versus* 10.6       60.0 *versus* 17.5   16.0 *versus* 6.6)        17.0 *versus* 3.6                 Mortality

  Ruan *et al.*^[@bibr24-1753466620937175]^     Retrospective Observational   150 (68/82)      67 *versus* 50                                                                                              72 *versus* 65       N/A      N/A          N/A            N/A              1297.6 *versus* 614     18.0 *versus* 16.0       43.0 *versus* 28.0   19.0 *versus* 0)          3.0 *versus* 1.0                  Mortality

  Zhou *et al.*^[@bibr23-1753466620937175]^     Retrospective Observational   191 (54/137)     69.0 *versus* 52.0                                                                                          70 *versus* 59       N/A      N/A          ⩾0.5 ng/ml     \>0.1 mg/L       1435.3 *versus* 503.2   31.0 *versus* 14.0       48.0 *versus* 23.0   24.0 *versus* 1.0         7.0 *versus* 1.0                  Mortality

  Cao *et al.*^[@bibr21-1753466620937175]^      Retrospective Observational   102 (17/85)      72 *versus* 53                                                                                              76.5 *versus* 47.1   CRP      ⩾ 10 mg/L    ⩾0.1 ng/ml     ⩾500 mg/L        N/A                     35.3 *versus* 5.9        64.7 *versus* 20.0   17.6 *versus* 2.4         23.5 *versus* 7.1                 Mortality

  Cai *et al.*^[@bibr20-1753466620937175]^      Retrospective Observational   298 (58/240)     64 *versus* 40                                                                                              56.9 *versus* 46.3   CRP      \>8 U/L      N/A            \>0.5 mg/L       N/A                     6.4                      12.8                 3.7                       N/A                               Severe COVID-19

  Guan *et al.*^[@bibr19-1753466620937175]^     Retrospective Observational   1099 (173/926)   52.0 *versus* 45.0                                                                                          57.8 *versus* 38.2   CRP      ⩾10 mg/L     ⩾0.5 ng/ml     ⩾ 0.5 mg/L       N/A                     16.2 *versus* 5.7        23.7 *versus* 13.4   5.8 *versus* 1.8          3.5 *versus* 0.6                  Severe COVID-19

  Hu *et al.*^[@bibr18-1753466620937175]^       Retrospective Observational   323 (172/151)    65 *versus* 56                                                                                              52.9 *versus* 49.7   CRP      ⩾3 mg/L      \>0.1 ng/ml    \>0.5 mg/L       N/A                     19.2 *versus* 9.3        38.3 *versus* 25.8   19.2 *versus* 5.3 (CVD)   3.5 *versus* 0                    Severe COVID-19

  Tabata *et al.*^[@bibr17-1753466620937175]^   Retrospective Observational   104 (28/76)      68 (total)                                                                                                  45.2 (total)         CRP      \>10 mg/L    N/A            N/A              N/A                     6.7 (total)              N/A                  29.8 (total)              6.7 (unspecified)                 Severe COVID-19

  Zhang *et al.*^[@bibr16-1753466620937175]^    Retrospective Observational   140 (58/82)      \<30 (1.7 *versus* 4.9), 30--49 (15.5 *versus* 34.1), 50--69 (48.3 *versus* 50), ⩾70 (34.5 *versus* 11.0)   56.9 *versus* 46.3   CRP      \>3 mg/L     \>0.1 ng/ml    \>0.243 mg/L     N/A                     13.8 *versus* 11.0       37.9 *versus* 24.4   6.9 *versus* 3.7          3.4 *versus* 0                    Severe COVID-19

  Zhao *et al.*^[@bibr15-1753466620937175]^     Retrospective Observational   77 (57/20)       69 *versus* 45                                                                                              55 *versus* 40.4     CRP      ⩾10 mg/L     N/A            N/A              N/A                     10.0 *versus* 7.0        40.0 *versus* 14.0   30.0 *versus* 5.3         15.0 *versus* 5.3 (unspecified)   Severe COVID-19

  Zhang *et al.*^[@bibr14-1753466620937175]^    Retrospective Observational   221 (55/166)     62 *versus* 51                                                                                              63.6 *versus* 44.0   N/A      N/A          ⩾1 ng/ml       N/A              N/A                     10 (12.7 *versus* 9.0)   47.3 *versus* 16.9   23.6 *versus* 5.4         7.3 *versus* 1.2                  Severe COVID-19

  Wan *et al.*^[@bibr13-1753466620937175]^      Retrospective Observational   135 (40/135)     56 *versus* 44                                                                                              52.5 *versus* 54.7   N/A      N/A          ⩾0.25 ng/ml    N/A              N/A                     22.5 *versus* 3.1        10 *versus* 9.4      15.0 *versus* 1.0 (CVD)   2.5 *versus* 0 (CLD)              Severe COVID-19

  Li *et al.*^[@bibr12-1753466620937175]^       Retrospective Observational   325 (26/299)     65 *versus* 49                                                                                              76.9 *versus* 49.2   N/A      N/A          ⩾0.5 ng/ml     N/A              N/A                     19.2 *versus* 8.4        46.2 *versus* 22.1   19.2 *versus* 4.3         7.7 *versus* 0.6                  Severe COVID-19

  Wang *et al.*^[@bibr34-1753466620937175]^     Retrospective Observational   143 (71/72)      65 *versus* 44                                                                                              62 *versus* 40.3     N/A      N/A          ⩾0.5 ng/ml     N/A              N/A                     12.7 *versus* 5.6        43.7 *versus* 6.9    16.9 *versus* 5.6         9.9 *versus* 4.2                  Severe COVID-19

  Ji *et al.* ^[@bibr33-1753466620937175]^      Retrospective Observational   49 (15/34)       56.5 *versus* 37.9                                                                                          66.7 *versus* 61.8   N/A      N/A          N/A            N/A              907.4 *versus* 318.1    N/A                      N/A                  N/A                       N/A                               Severe COVID-19

  Liu *et al.*^[@bibr32-1753466620937175]^      Retrospective Observational   40 (13/40)       59.7 *versus* 43.2                                                                                          53.8 *versus* 29.6   N/A      N/A          N/ A           N/A              835.5 *versus* 367.8    30.8 *versus* 7.4        38.5 *versus* 3.7    N/A                       N/A                               Severe COVID-19

  Liu *et al.*^[@bibr31-1753466620937175]^      Retrospective Observational   80 (69/11)       56 *versus* 31                                                                                              47.8 *versus* 9.09   CRP      ⩾10 mg/L     ⩾ 0.5 ng/ml    ⩾0.5 mg/L        827.2 *versus* 155.7    15.9 *versus* 0          20.3 *versus* 0      8.7 *versus* 0            N/A                               Severe COVID-19

  Ma *et al.*^[@bibr30-1753466620937175]^       Retrospective Observational   84 (20/64)       58 *versus* 46.5                                                                                            60 *versus* 56.3     N/A      N/A          N/ A           N/A              1104 *versus* 368.5     35 *versus* 4.7          20.0 *versus* 12.5   10.0 *versus* 4.7         10.0 *versus* 4.7 (CLD)           Severe COVID-19

  Qin *et al.*^[@bibr29-1753466620937175]^      Retrospective Observational   452 (286/166)    61 *versus* 53                                                                                              54.2 *versus* 48.2   N/A      N/A          N/ A           N/A              800.4 *versus* 523.7    18.5 *versus* 13.3       36.7 *versus* 18.1   8.4 *versus* 1.8 (CVD)    3.1 *versus* 1.8                  Severe COVID-19

  Chen *et al.*^[@bibr28-1753466620937175]^     Retrospective Observational   21 (11/10)       61 *versus* 52                                                                                              90.9 *versus* 70     hs-CRP   \>60 mg/L    ⩾0.5 ng/ml     N/A              1598.2 *versus* 337.4   18.2 *versus* 10.2       36.4 *versus* 10.0   N/A                       N/A                               Severe COVID-19

  Cao *et al.*^[@bibr22-1753466620937175]^      Retrospective Observational   198 (19/176)     63.7 *versus* 48.6                                                                                          89.5 *versus* 46.9   hs-CRP   ⩾10 mg/L     \>0.05 ng/ml   \>0.5 mg/L       N/A                     10.5 *versus* 7.3        31.6 *versus* 20.1   26.3 *versus* 3.9 (CVD)   N/A                               ICU care

  Wang *et al.*^[@bibr11-1753466620937175]^     Retrospective Observational   138 (36/102)     66 *versus* 51                                                                                              61.1 *versus* 52.0   N/ A     N/A          ⩾0.05 ng/ml    N/A              N/A                     22.2 *versus* 5.9        58.3 *versus* 21.6   25.0 *versus* 10.8        8.3 *versus* 1.0                  ICU care

  Wu *et al.*^[@bibr10-1753466620937175]^       Retrospective Observational   201 (84/117)     58.5 *versus* 48                                                                                            71.4 *versus* 58.1   N/A      N/A          N/A            N/A              1029.3 *versus* 545.5   19 *versus* 5.1          27.4 *versus* 13.7   6.0 *versus* 2.6          2.5 (total) (CLD)                 ARDS
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Data are presented as poor outcome *versus* non-poor outcome.

ARDS, acute respiratory distress syndrome; CAD, coronary artery disease; CLD, chronic lung/pulmonary disease; COPD, chronic obstructive pulmonary disease; COVID-19, coronavirus disease-2019; CRP, C-reactive protein; CVD, cardiovascular disease; DM, diabetes mellitus; hs-CRP, high sensitive C-reactive protein; HTN, hypertension; ICU, intensive care unit; N/A, not available ; PCT, procalcitonin; Unspecified, respiratory comorbidities not otherwise specified in the study.

Elevated CRP and outcome {#section13-1753466620937175}
------------------------

This meta-analysis of 13 studies showed that an elevated serum CRP was associated with an increased composite poor outcome \[RR 1.84 (1.45, 2.33), *p* \< 0.001; I^2^: 96%, *p* \< 0.001\] ([Figure 2(a)](#fig2-1753466620937175){ref-type="fig"}).^[@bibr15-1753466620937175][@bibr16-1753466620937175][@bibr17-1753466620937175][@bibr18-1753466620937175][@bibr19-1753466620937175][@bibr20-1753466620937175][@bibr21-1753466620937175]--[@bibr22-1753466620937175],[@bibr25-1753466620937175][@bibr26-1753466620937175][@bibr27-1753466620937175]--[@bibr28-1753466620937175],[@bibr31-1753466620937175]^ Subgroup analysis showed that an elevated CRP was associated with an increased risk of severe COVID-19 \[RR 1.41 (1.14, 1.74), *p* = 0.002; I^2^: 93%, *p* \< 0.001\], need for ICU care \[RR 1.96 (1.40, 2.74), *p* \< 0.001\], but not mortality \[RR 2.95 (0.90, 9.68), *p* = 0.07; I^2^: 99%, *p* \< 0.001\]. Sensitivity analysis showed that heterogeneity cannot be reduced by removing one study. The cutoff values used to determine elevated serum CRP varied widely among the studies.

![Elevated CRP and composite poor outcome. (a) Patients with a composite poor outcome comprising mortality, ARDS, need for ICU care, and severe COVID-19 have an elevated serum CRP. (b) SROC analysis (with prediction and confidence contours) of an elevated CRP and a composite poor outcome. ^(1)^Cao *et al.*,^[@bibr21-1753466620937175]\ (2)^Guan *et al.*,^[@bibr19-1753466620937175]\ (3)^Tabata *et al.*,^[@bibr17-1753466620937175]\ (4)^Zhao *et al.*,^[@bibr15-1753466620937175]\ (5)^Liu *et al.*^[@bibr31-1753466620937175]^\
ARDS, acute respiratory distress syndrome; AUC, area under curve; CI, confidence interval; COVID-19, coronavirus disease-2019; CRP, C-reactive protein; df, degrees of freedom; ICU, intensive care unit. SROC, summary receiver operating characteristic.](10.1177_1753466620937175-fig2){#fig2-1753466620937175}

Pooled analysis of a single cutoff point of ⩾10 mg/L resulted in a sensitivity of 51% (18--84%) and a specificity of 88% (70--95%). Summary of receiver operating characteristic (SROC) curve analysis (with prediction and confidence contours) demonstrated an area under curve (AUC) of 0.84 (0.80--0.87) ([Figure 2(b)](#fig2-1753466620937175){ref-type="fig"}). A CRP ⩾10 mg/L has an likelihood ratio (LR) + of 4.1 and an LR- of 0.5.

Elevated PCT and outcome {#section14-1753466620937175}
------------------------

An elevated PCT was associated with an increased composite poor outcome \[RR 3.92 (2.42, 6.35), *p* \< 0.001; I^2^: 85%, *p* \< 0.001\] ([Figure 3(a)](#fig3-1753466620937175){ref-type="fig"}) in 16 studies.^[@bibr11-1753466620937175][@bibr12-1753466620937175][@bibr13-1753466620937175]--[@bibr14-1753466620937175],[@bibr16-1753466620937175],[@bibr18-1753466620937175],[@bibr19-1753466620937175],[@bibr21-1753466620937175][@bibr22-1753466620937175]--[@bibr23-1753466620937175],[@bibr25-1753466620937175][@bibr26-1753466620937175][@bibr27-1753466620937175]--[@bibr28-1753466620937175],[@bibr31-1753466620937175],[@bibr34-1753466620937175]^ Subgroup analysis showed that an elevated PCT was associated with increased mortality \[RR 6.26 (1.75, 22.42), *p* = 0.005; I^2^: 96%, *p* \< 0.001\]and severe COVID-19 \[RR 3.93 (2.01, 7.67), *p* \< 0.001; I^2^: 63%, *p* = 0.006\]. However, an elevated PCT was not associated with an increased need for ICU care \[RR 1.89 (0.51, 6.99), *p* = 0.34; I^2^: 88%, *p* = 0.003\]. By removing the Li *et al.* study,^[@bibr12-1753466620937175]^ sensitivity analysis reduced heterogeneity for severe COVID-19 \[RR 2.90 (1.76, 4.77), *p* \< 0.001; I^2^: 41%, *p* = 0.10\].

![Elevated PCT and composite poor outcome. (a) Patients with a composite poor outcome comprising mortality, ARDS, need for ICU care, and severe COVID-19 have an elevated serum PCT. (b) SROC analysis (with prediction and confidence contours) of elevated PCT and composite poor outcome. ^(1)^Chen *et al.*,^[@bibr27-1753466620937175]\ (2)^Luo *et al.*,^[@bibr25-1753466620937175]\ (3)^Zhou *et al.*,^[@bibr23-1753466620937175]\ (4)^Guan *et al.*,^[@bibr19-1753466620937175]\ (5)^Wang *et al.*,^[@bibr34-1753466620937175]\ (6)^Liu *et al.*,^[@bibr31-1753466620937175]\ (7)^Chen *et al.*^[@bibr28-1753466620937175]^\
ARDS, acute respiratory distress syndrome; AUC, area under curve; CI, confidence interval; COVID-19, coronavirus disease-2019; df, degrees of freedom; ICU, intensive care unit; PCT, procalcitonin; SROC, summary receiver operating characteristic.\
Pooled analysis of a single cutoff point of ⩾0.5 ng/ml resulted in a sensitivity of 88% (70--96%) and a specificity of 68% (47--84%). SROC curve analysis demonstrated an AUC of 0.88 (0.84--0.90) ([Figure 3(b)](#fig3-1753466620937175){ref-type="fig"}). PCT ⩾0.5 ng/ml has an LR+ of 2.7 and an LR- of 0.2.](10.1177_1753466620937175-fig3){#fig3-1753466620937175}

Elevated D-dimer and outcome {#section15-1753466620937175}
----------------------------

The meta-analysis of 11 studies showed that an elevated D-dimer was associated with an increase in composite poor outcome \[RR 2.93 (2.14, 4.01), *p* \< 0.001; I^2^: 77%, *p* \< 0.001\] ([Figure 4(a)](#fig4-1753466620937175){ref-type="fig"}).^[@bibr16-1753466620937175][@bibr17-1753466620937175][@bibr18-1753466620937175][@bibr19-1753466620937175][@bibr20-1753466620937175][@bibr21-1753466620937175][@bibr22-1753466620937175]--[@bibr23-1753466620937175],[@bibr25-1753466620937175][@bibr26-1753466620937175]--[@bibr27-1753466620937175],[@bibr31-1753466620937175]^ Subgroup analysis showed that an elevated D-dimer was associated with increased mortality \[RR 4.15 (2.43, 7.08), *p* \< 0.001; I^2^: 83%, *p* = 0.01\], severe COVID-19 \[RR 2.42 (1.72, 3.40), *p* \< 0.001; I^2^: 58%, *p* = 0.05\], but not the need for ICU care \[RR 0.94 (0.43, 2.07), *p* = 0.88\]. By removing the Hu *et al.* study, ^[@bibr18-1753466620937175]^ sensitivity analysis reduced heterogeneity for severe COVID-19 \[RR 2.77 (2.06, 3.73), *p* \< 0.001; I^2^: 19%, *p* = 0.30\].

![Elevated D-dimer and composite poor outcome. (a) Patients with a composite poor outcome comprising mortality, ARDS, need for ICU care, and severe COVID-19 have an elevated serum PCT. (b) SROC analysis (with prediction and confidence contours) of elevated D-dimer and a composite poor outcome. ^(1)^Cai *et al.*,^[@bibr20-1753466620937175]\ (2)^ Guan *et al.*,^[@bibr19-1753466620937175]\ (3)^Hu *et al.*,^[@bibr18-1753466620937175]\ (4)^Liu *et al.*,^[@bibr31-1753466620937175]\ (5)^Cao *et al.*^[@bibr22-1753466620937175]^\
ARDS, acute respiratory distress syndrome; AUC, area under curve; CI, confidence interval; COVID-19, coronavirus disease-2019; df, degrees of freedom; ICU, intensive care unit; PCT, procalcitonin; SROC, summary receiver operating characteristic.\
Pooled analysis of a single cutoff point of \>0.5 mg/L resulted in a sensitivity of 58% (18--90%) and a specificity of 69% (43--86%). SROC curve analysis (with prediction and confidence contours) demonstrated an AUC of 0.69 (0.65--0.73) ([Figure 4(b)](#fig4-1753466620937175){ref-type="fig"}). A D-dimer \>0.5 mg/L has an LR+ of 1.8 and an LR- of 0.6.](10.1177_1753466620937175-fig4){#fig4-1753466620937175}

Ferritin and poor outcome {#section16-1753466620937175}
-------------------------

Patients with a composite poor outcome had a higher ferritin level \[SMD 0.90 (0.64, 1.15), *p* \< 0.0001; I^2^: 76%\] ([Figure 5](#fig5-1753466620937175){ref-type="fig"}) in 10 studies.^[@bibr10-1753466620937175],[@bibr23-1753466620937175],[@bibr24-1753466620937175],[@bibr27-1753466620937175][@bibr28-1753466620937175][@bibr29-1753466620937175][@bibr30-1753466620937175][@bibr31-1753466620937175][@bibr32-1753466620937175]--[@bibr33-1753466620937175]^ Subgroup analysis results demonstrated that ferritin level was higher in non-survivors (mortality) \[SMD 0.96 (0.78, 1.13), *p* \< 0.00001; I^2^: 0%, *p* = 0.41\] and patients with severe COVID-19 \[SMD 0.97 (0.43, 1.50), *p* \< 0.004; I^2^: 82%, *p* = 0.001\].

![Higher serum ferritin and a composite poor outcome. Patients with a composite poor outcome comprising mortality, ARDS, need for ICU care, and severe COVID-19 have a higher serum ferritin level.\
ARDS, acute respiratory distress syndrome; CI, confidence interval; COVID-19, coronavirus disease-2019; df, degrees of freedom; ICU, intensive care unit.](10.1177_1753466620937175-fig5){#fig5-1753466620937175}

Meta-regression {#section17-1753466620937175}
---------------

Meta-regression analysis demonstrated that the association between an elevated CRP, PCT, D-dimer, serum ferritin level, and the composite poor outcome was not significantly affected by gender, age, hypertension, cardiovascular disease, diabetes, and COPD (*p* \> 0.05).

Publication bias {#section18-1753466620937175}
----------------

The funnel-plot was qualitatively asymmetrical for D-dimer, PCT, CRP, and ferritin. Regression-based Egger's test showed no indication of small-study effects for D-dimer (*p* = 0.073) and ferritin (*p* = 0.372) on the composite poor outcome. There was indication of small-study effects in the association between PCT (*p* = 0.003), CRP (*p* \< 0.001), and a composite poor outcome.

Discussion {#section19-1753466620937175}
==========

This meta-analysis showed that elevated serum CRP, PCT, D-dimer, and serum ferritin levels were associated with an increased composite poor outcome that comprises mortality, severe COVID-19, ARDS, and the need for ICU care in patients with COVID-19. The effect estimate was not significantly modified by gender, age, cardiovascular disease, diabetes, and COPD.

In the systemic hyperinflammation phase of COVID-19 proposed by Siddiqi and Mehra,^[@bibr35-1753466620937175]^ there is a significant elevation of inflammatory cytokines and biomarkers, such as interleukin (IL)-2, IL-6, IL-7, granulocyte-colony stimulating factor, macrophage inflammatory protein 1-α, tumor necrosis factor-α (TNF-α), CRP, ferritin, PCT, and D-dimer. This stage consists of the most severe manifestation of the cytokine storm, in which excessive hyperinflammation may lead to cardiopulmonary collapse and multi-organ failure.^[@bibr35-1753466620937175],[@bibr36-1753466620937175]^

CRP is an acute phase inflammatory protein produced by the liver that may be elevated in several conditions, such as inflammation, cardiovascular disease, and infection.^[@bibr37-1753466620937175]^ In our meta-analysis of 13 studies, an elevated CRP was associated with severe COVID-19, the need for ICU care, but not with mortality. Although there is no general agreement on a cutoff point to determining the severity of COVID-19, the majority of the studies used a ⩾10 mg/L cutoff. Our SROC analysis showed the diagnostic value of serum CRP ⩾10 mg/L for a composite poor outcome in COVID-19 (51% sensitivity, 88% specificity, an LR+ of 4.1 and an LR- of 0.5). Previous studies that attempted to predict mortality in sepsis by the presence of an elevated serum CRP were inconclusive. A study showed that an elevated serum CRP level was associated with a 30-day mortality rate,^[@bibr38-1753466620937175]^ while other studies showed otherwise.^[@bibr39-1753466620937175][@bibr40-1753466620937175]--[@bibr41-1753466620937175]^ These inconsistencies might be caused by the different cutoff values used. In the study by Koozi *et al.*, the cutoff value for an elevated serum CRP was ⩾1000 mg/L,^[@bibr38-1753466620937175]^ while in the study by Ryoo *et al.*, the cutoff point of ⩾140 mg/L was used.^[@bibr41-1753466620937175]^ Liu *et al.* proposed a cutoff value of ⩾41.8 mg/L to predict severe COVID-19.^[@bibr42-1753466620937175]^ In our analysis, the cutoff values of serum CRP varied widely, with the lowest and highest values being \>3 mg/L and \>100 mg/L, respectively. These findings reflected the paramount need for pursuing the optimal serum CRP cutoff value for COVID-19 prognostication. The time period for serum CRP measurement was critical in light of the timely manner of serum CRP increment, which culminates 72 h after the initial insults.^[@bibr37-1753466620937175],[@bibr41-1753466620937175]^ Despite its value in predicting a poor outcome in COVID-19, it should be noted that various factors could affect serum CRP levels, including age, gender, smoking status, weight, lipid levels, blood pressure, and liver injury.^[@bibr37-1753466620937175]^ These factors should be taken into account while interpreting the serum CRP level. In addition, recent evidence has shown that serum CRP level could also be used in monitoring the progression and improvement of patients with COVID-19.^[@bibr43-1753466620937175]^

A peptide precursor of the hormone calcitonin, PCT, has been widely investigated as a promising biomarker for the initial investigation of a bacterial infection.^[@bibr44-1753466620937175]^ An elevated serum PCT is often found in patients with sepsis and septic shock.^[@bibr39-1753466620937175]^ While it is still controversial whether PCT can accurately distinguish bacterial or viral pneumonia,^[@bibr45-1753466620937175]^ it was found that PCT-guided therapy in acute respiratory infections reduces the antibiotic exposure and side effects, and improves the survival rate.^[@bibr46-1753466620937175]^ Bacterial infections trigger extrathyroidal synthesis of PCT, which is actively maintained by elevated values of IL-6, IL-1β, and TNF-α, while viral infections hinder PCT production due to interferon-γ.^[@bibr47-1753466620937175]^ This explains why serum PCT concentrations remain normal in uncomplicated cases of COVID-19 and inflated values may indicate bacterial co-infection in severe cases.^[@bibr48-1753466620937175]^ In this meta-analysis, we found that an elevated serum PCT was associated with mortality and severe COVID-19. Our SROC analysis showed the diagnostic value of serum PCT ⩾0.5 mg/L for a composite poor outcome in COVID-19 (88% sensitivity, 68% specificity, LR+ 2.7 and LR- 0.2).

In our study, we also found that an elevated D-dimer was associated with an increased composite poor outcome, especially mortality and severe COVID-19. This finding supports the hypothesis that severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection could induce the dysfunction of the hemostatic system, leading to a hypercoagulable state, a condition which we commonly encounter in sepsis.^[@bibr49-1753466620937175],[@bibr50-1753466620937175]^ Recent evidence of lung pathology dissection has shown occlusion and micro-thrombosis formation in pulmonary small vessels of patients critically ill with COVID-19.^[@bibr51-1753466620937175]^ However, the etiology of elevated serum D-dimer level is multifactorial and the optimal cutoff value of elevated D-dimer in patients with COVID-19 remains to be established. It is clear that COVID-19-associated coagulopathy warrants distinct emphasis and special treatment. According to the International Society of Thrombosis and Hemostasis (ISTH) guideline, a markedly elevated serum D-dimer level (which is still poorly defined as a three- to four-fold increase) implies an increased thrombin production. Patients with COVID-19 with markedly elevated D-dimer levels may require hospitalization, despite the severity of clinical presentation.^[@bibr52-1753466620937175]^ In the absence of contraindications, a prophylactic dose of an anticoagulant is recommended for all hospitalized patients with COVID-19.

Along with other biomarkers included in this study, we also found that a higher serum ferritin level was independently associated with ARDS, mortality, and severe COVID-19. This may lead to the notion of the presence of secondary hemophagocytic lymphohistiocytosis (sHLH) in COVID-19.^[@bibr7-1753466620937175]^ sHLH is a condition of hyperinflammation characterized by a cytokine storm causing fatal multi-organ failure.^[@bibr53-1753466620937175]^ This condition is most commonly triggered by viral infections,^[@bibr54-1753466620937175]^ which might lead to a hypothesis of SARS-CoV-2 inducing this hyperinflammatory syndrome. Despite the fact that some authors suggested using HScore to identify subgroups of patients that may benefit from immunosuppressive therapy,^[@bibr7-1753466620937175]^ it is still controversial whether or not this specific condition in severe COVID-19 needs to be treated as in sHLH. A recent systematic review by Veronese *et al.* including 542 patients reported conflicting evidence in 4 studies.^[@bibr55-1753466620937175]^ The authors concluded that the current evidence did not support the routine use of corticosteroids in COVID-19, but some findings suggested corticosteroids may reduce the mortality rate in COVID-19 cases aggravated with ARDS.

Clinical implication {#section20-1753466620937175}
--------------------

An elevated serum CRP, PCT, D-dimer, and ferritin can be used as laboratory biomarkers for a poor outcome in COVID-19. The cutoff points of elevated CRP (⩾10 mg/L), PCT (⩾0.5 ng/mL), and D-dimer (\>0.5 mg/L) are suggested based on the current evidence, even though higher cutoff values might reflect a poorer outcome. Serum CRP may not only be used as a prognostic marker, but also to monitor disease improvement in COVID-19. Elevated serum PCT might be useful in guiding antibiotic therapy for bacterial superinfection, although further studies are warranted. Based on our findings on the association between serum D-dimer levels and a poor outcome in COVID-19, we support the current ISTH guideline on the use of a prophylactic anticoagulant in patients with COVID-19.^[@bibr52-1753466620937175]^ We also encourage further studies to create a prognostic model that includes these biomarkers along with other proven poor prognostic factors in COVID-19.^[@bibr6-1753466620937175],[@bibr56-1753466620937175],[@bibr57-1753466620937175]^

Limitations {#section21-1753466620937175}
-----------

The limitations of this systematic review and meta-analysis were the possible presence of publication bias, the use of non-peer-reviewed studies, and the nature of retrospective studies. The asymmetrical inverted funnel-plot for serum D-dimer, PCT, CRP, and ferritin implied the presence of publication bias. We included studies published on preprints servers and which were not yet peer-reviewed. This was due to the emergent pandemic situation of COVID-19, during which data from preprints servers might be crucial, despite the drawbacks. Most of the studies were from a single country, thus the patients might overlap across reports. All the included studies were mostly retrospective and observational, therefore, the results must be cautiously interpreted.

Conclusion {#section22-1753466620937175}
==========

This meta-analysis showed that an elevated serum CRP, PCT, D-dimer, and serum ferritin were associated with a composite poor outcome in patients with COVID-19.
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